The modifying effect of mutant LRRK2 on mutant GBA1 -associated Parkinson disease
Human Molecular Genetics · 2025
DOI: 10.1093/hmg/ddaf062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, 2025. Verfasst von Vera Serebryany-Piavsky und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shmunis School of Biomedicine and Cancer Research, Tel-Aviv University, Levanon St., Tel Aviv 69978, Israel. Hauptthemen laut MEDLINE: Parkinson Disease, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Glucosylceramidase, Drosophila Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aufzien Center for the Prevention of Parkinson disease at Tel Aviv University, Israel Science Foundation, United States-Israel Binational Science Foundation.
Abstract (Originalsprache)
Parkinson disease (PD) is the second most common neurodegenerative disease. While most cases are sporadic, in ~ 5%–10% of PD patients the disease is caused by mutations in several genes, among them GBA1 (glucocerebrosidase beta 1) and LRRK2 (leucine-rich repeat kinase 2), both prevalent among the Ashkenazi Jewish population. LRRK2-associated PD tends to be milder than GBA1-associated PD. Several recent clinical studies have suggested that carriers of both GBA1 and LRRK2 mutations develop milder PD compared to that observed among GBA1 carriers. These findings strongly suggested an interplay between the two genes in the development and progression of PD. In the present study Drosophila was employed as a model to investigate the impact of mutations in the LRRK2 gene on mutant GBA1-associated PD. Our results strongly indicated that flies expressing both mutant genes exhibited milder parkinsonian signs compared to the disease developed in flies expressing only a GBA1 mutation. This was corroborated by a decrease in the ER stress response, increase in the number of dopaminergic cells, elevated levels of tyrosine hydroxylase, reduced neuroinflammation, improved locomotion and extended survival. Furthermore, a significant decrease in the steady-state levels of mutant GBA1-encoded GCase was observed in the presence of mutant LRRK2, strongly implying a role for mutant LRRK2 in degradation of mutant GCase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shmunis School of Biomedicine and Cancer Research, Tel-Aviv University, Levanon St., Tel Aviv 69978, Israel.
- Department of Physiology and Pharmacology, Faculty of Medicine, Tel Aviv University, Levanon St., Tel Aviv 69978, Israel.
- Movement Disorders Institute, Department of Neurology, Sheba Medical Center, Tel-Hashomer, Ramat-Gan 52620, Israel.
- Sagol School of Neuroscience, Tel Aviv University, Levanon St., Tel Aviv 69978, Israel.
Förderung
- Aufzien Center for the Prevention of Parkinson disease at Tel Aviv University
- Israel Science Foundation
- United States-Israel Binational Science Foundation
Zitieren
APA
Serebryany-Piavsky, V., Egulsky, L., Manoim-Wolkovitz, J. E., Anis, S., Hassin-Baer, S., Parnas, M., & Horowitz, M. (2025). The modifying effect of mutant LRRK2 on mutant GBA1 -associated Parkinson disease. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddaf062
Vancouver
Serebryany-Piavsky V, Egulsky L, Manoim-Wolkovitz JE, Anis S, Hassin-Baer S, Parnas M, et al. The modifying effect of mutant LRRK2 on mutant GBA1 -associated Parkinson disease. Human Molecular Genetics. 2025. doi:10.1093/hmg/ddaf062
BibTeX
@article{SerebryanyPiavsky2025,
author = {Serebryany-Piavsky, Vera and Egulsky, Lian and Manoim-Wolkovitz, Julia Elia and Anis, Saar and Hassin-Baer, Sharon and Parnas, Moshe and Horowitz, Mia},
title = {The modifying effect of mutant LRRK2 on mutant GBA1 -associated Parkinson disease},
journal = {Human Molecular Genetics},
year = {2025},
doi = {10.1093/hmg/ddaf062}
}
EUVIMED